arrow
V

Victor E. Velculescu

bloomberg kimmel institute for cancer immunotherapy at johns hopkins
H指数:128
被引数:11.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cell-free DNA fragmentomes for noninvasive detection of liver cirrhosis and other diseases

无细胞DNA片段组用于非侵入性检测肝硬化和其他疾病

2026-03-040
PRE
Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

帕博利珠单抗联合表观遗传修饰(阿扎胞苷)重塑铂耐药上皮性卵巢癌的肿瘤微环境:一项II期非随机临床试验

2026-02-060
OA
Phase II study of efficacy and safety of palbociclib in patients with recurrent ovarian cancer

帕博西利(palbociclib)在复发性卵巢癌患者中的有效性和安全性II期研究

2025-07-280
OAAI
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer

帕博利珠单抗联合放疗在免疫冷型非小细胞肺癌中诱导系统性抗肿瘤免疫应答

2025-07-220
OA
Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer

细胞自由DNA的全基因组分析用于胰腺癌患者的治疗监测

2025-05-230
PRE
Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer

ctDNA指导的 ⅱ 期结肠癌辅助化疗选择的有效性和成本-效果的早期评价

2024-08-212
OAAI
Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
2024-06-064
OAAI
Monitoring treatment response in patients with metastatic colorectal cancer using cfDNA fragmentomics testing: The DOLPHIN trial
2024-03-220
PRE
Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: The PROVENC3 study
2024-03-220
PRE